(0.41%) 5 112.50 points
(0.84%) 38 704 points
(0.69%) 17 772 points
(0.20%) $79.11
(0.00%) $2.04
(-0.04%) $2 308.60
(-0.20%) $26.78
(1.70%) $979.00
(-0.14%) $0.931
(-0.69%) $10.92
(-0.18%) $0.796
(0.46%) $91.55
Live Chart Being Loaded With Signals
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL)...
Stats | |
---|---|
今日成交量 | 3 615.00 |
平均成交量 | 14 170.00 |
市值 | 72.97M |
EPS | $0 ( 2024-03-29 ) |
下一个收益日期 | ( $-2.16 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.470 |
ATR14 | $0.0680 (0.61%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-10 | Laumas Sandeep | Buy | 80 000 | Employee Stock Option (right to buy) |
2024-02-10 | Crouch Bronson | Buy | 120 000 | Employee Stock Option (right to buy) |
2023-06-14 | Binder Gwendolyn | Buy | 1 500 | Stock Option (Right to Buy) |
2023-06-14 | Mcgaughy R Kent Jr | Buy | 1 500 | Stock Option (Right to Buy) |
2023-06-14 | Gibson Neil W | Buy | 1 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
97.91 |
Last 92 transactions |
Buy: 125 955 560 | Sell: 140 779 900 |
Till Capital Ltd. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-4.76M (0.00 %) |
EPS: | $-24.00 |
FY | 2023 |
营收: | $0 |
毛利润: | $-4.76M (0.00 %) |
EPS: | $-24.00 |
FY | 2022 |
营收: | $0 |
毛利润: | $-5.99M (0.00 %) |
EPS: | $-34.46 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Till Capital Ltd.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。